Compounds, biological data

For all three compounds, biological data relevant to the evaluation of carcinogenic risk to humans are summarized in the World Health Organization International Agency for Research on Cancer monograph (70). 

In the case of chemoinformatics this process of abstraction will be performed mostly to gain knowledge about the properties of compounds. Physical, chemical, or biological data of compounds will be associated with each other or with data on the structure of a compound. These pieces of information wQl then be analyzed by inductive learning methods to obtain a model that allows one to make predictions. 

Chemical compounds can also be represented by chemical data, or even by biological data. In fact, Briem et al. have used the results of a battery of biological assays to represent a compound for the modeling of other biological data [62-64]. 

Principal components analysis can also be used in the case when the compounds are characterized by multiple activities instead of a single one, as required by the Hansch or Free-Wilson models. This leads to the multivariate bioassay analysis which has been developed by Mager [9]. By way of illustration we consider the physicochemical and biological data reported by Schmutz [41] on six oxazepines... 

A series of dioxane carbamate inhibitors has recently been disclosed by Sanofi-Aventis. No biological data are provided for specific compounds, although most compounds are described as having IC50 values for FAAH inhibition ranging from 0.005-1 Compound (59) is one of over 25 compounds specifically claimed [74]. 

AM1241 (360) exhibited high affinity and selectivity for CB2 [it (CBi) = 280 nM, (CB2) = 3.4 nM]. (360) Dose dependently inhibited experimental neuropathic pain in a spinal nerve ligation-induced tactile and thermal hypersensitivity model [224]. Other indole derivatives bearing sulfonamide moieties on the side chain, such as compound (361), were disclosed [225]. Though 67 derivatives including pyridyl and other heteroaromatics instead of the indole core were listed, no specific biological data were shown. 

Stated to be particularly useful in the treatment of obesity, a series of 1,5-diaryl-pyrrole-based compounds from AstraZeneca was claimed in a recent patent application [313], including compound (509). Although no specific biological data were presented, the CBi receptor affinities are claimed to be less than 1 pM and preferably less than 200 nM. 

Obtaining a good quality QSAR model depends on many factors, such as the quality of biological data and the choice of descriptors and statistical methods. As a consequence, the uncertainty of the QSAR predictions is a combination of experimental uncertainties and model uncertainties. QSAR methods have to be applied to individual chemicals, not on mixtures. If the QSAR demands it, the components of the mixture have to be addressed separately and individually - in case of unknown compounds, QSAR cannot identify the toxicity risk and is therefore not useful. 

Apparently related to the aforementioned xanthine analogs, pyridopyrimidinone (X =X2=X3=CH or CR) and aza-pyridopyrimidinone (X1 or X3=N, X2=CH or CR) derivatives (M), exemplified by compounds 41 and 42 respectively, were discovered as GPR109A agonists [94,95]. So far no biological data has been provided for this class of molecules. The calculated pKa of the N-H group present in compounds 41 and 42 ranges from 8 to 9 [82]. 

The aziridines are the nitrogen analogs of the epoxides and undergo similar electrophilic reactions. No biological data were obtained for these compounds nor were they used as precursors to any CA-4, 7, analogs. They have been included since the synthesis is noteworthy, and they could be interesting intermediates. Xu et al. stereoselectively aziridinated chalcones using the nitrene precursor (PhINTS) and a copper catalyst to form compound 141 (Scheme 36) [82],... 

The synthesis of biologically important heterocyclic stilbene and chalcone derivatives of combretastatins has been discussed. Combretastatins have been shown to be inhibitors of tubulin polymerization. In many cases the compounds described in this chapter were included because of an interesting synthesis or structure, although limited biological data were found. It is the author s opinion that a great number of the compounds contained within this review are worthy of further investigation as potential tubulin binders. 

Each screening center has medicinal and synthetic chemistry expertise in order to optimize hits identified from HTS campaigns and develop them into chemical probes. Specific capabilities vary, however typical strategies employed include parallel synthesis, computational and informatics analysis, and analytical capabilities such as LC/MS techniques. The structures of novel compounds that are prepared, their synthetic protocols, analytical data and biological data are all available, and samples of final probes developed are deposited into the MLSMR. A Working Group comprised of chemists from each center meets regularly to share information, best practices, and insure optimal use of resources. 

---